Vernalis Therapeutics

Berwyn, Pennsylvania based Vernalis Therapeutics, Inc. is a distributor of pharmaceutical products, with a focus on the sales and marketing of branded prescription products in the US market.  Vernalis Therapeutics, Inc. is a US subsidiary of Vernalis plc, a UK based company, listed on AIM and founded in 2003 with an historic focus on drug discovery and clinical development.

Vernalis Therapeutics, Inc. is dedicated to building a broad portfolio of unique long-acting formulations of branded prescription cough cold products for the US market.

In October 2015, Vernalis also acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older.

 

 

Latest News

Unaudited Interim Results for the six months ended 31 December 2016

Vernalis plc (LSE: VER) today announces its unaudited consolidated results for the six month period ended 31 December 2016.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch